Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
Markus Pfirrmann(Ludwig-Maximilians-Universität München), Bengt Simonsson(Uppsala University Hospital), Francisco Cervantes(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Fausto Castagnetti(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Michele Baccarani(University of Bologna), Rüdiger Hehlmann, Joerg Hasford(German Medical Association), Verena Hoffmann(Zimmer Biomet (Germany)), G.J. Ossenkoppele(Amsterdam UMC Location Vrije Universiteit Amsterdam), Joëlle Guilhot(Inserm), Susanne Saußele(Heidelberg University)
Cited by 298
Related Papers
A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group
|JNCI Journal of the National Cancer Institute|1998|820
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
|Journal of Clinical Oncology|2005|573